BioAtla, Inc. (BCAB)
NASDAQ: BCAB · IEX Real-Time Price · USD
-0.180 (-7.89%)
At close: May 23, 2024, 4:00 PM
+0.090 (4.29%)
After-hours: May 23, 2024, 7:32 PM EDT

Company Description

BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer.

The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.

It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types.

The company was founded in 2007 and is headquartered in San Diego, California.

BioAtla, Inc.
BioAtla logo
Country United States
Founded 2007
IPO Date Dec 16, 2020
Industry Biotechnology
Sector Healthcare
Employees 65
CEO Dr. Jay M. Short Ph.D.

Contact Details

11085 Torreyana Road
San Diego, California 92121
United States
Phone 858-558-0708

Stock Details

Ticker Symbol BCAB
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $18.00
CIK Code 0001826892
CUSIP Number 09077B104
ISIN Number US09077B1044
Employer ID 85-1922320
SIC Code 2836

Key Executives

Name Position
Dr. Jay M. Short Ph.D. Co-Founder, Chief Executive Officer and Chairman
Richard A. Waldron Senior Vice President and Chief Financial Officer
Dr. Eric L. Sievers M.D. Chief Medical Officer
Christian J. Vasquez Chief Accounting Officer, Controller and Corporate Secretary
Susie Melody Senior Vice President of Human Resources
Dr. Cathy Chang Ph.D. Senior Vice President of Research and Development
Dr. Gerhard Frey Ph.D. Senior Vice President of Technology Development
Monica Sullivan Senior Vice President of Intellectual Property and Contracts
Sheri Lydick Chief Commercial Officer
Dr. Bin Zhang Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
May 17, 2024 8-K Current Report
May 14, 2024 10-Q Quarterly Report
May 14, 2024 8-K Current Report
Apr 24, 2024 8-K Current Report
Apr 24, 2024 ARS Filing
Apr 24, 2024 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2024 DEF 14A Other definitive proxy statements
Apr 16, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Mar 26, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 26, 2024 10-K Annual Report